DNA
Price
$9.44
Change
-$0.17 (-1.77%)
Updated
Jun 27 closing price
Capitalization
553.71M
PLX
Price
$1.54
Change
+$0.09 (+6.21%)
Updated
Jun 27 closing price
Capitalization
122.59M
49 days until earnings call
Interact to see
Advertisement

DNA vs PLX

Header iconDNA vs PLX Comparison
Open Charts DNA vs PLXBanner chart's image
Ginkgo Bioworks Holdings
Price$9.44
Change-$0.17 (-1.77%)
Volume$7.05M
Capitalization553.71M
Protalix BioTherapeutics
Price$1.54
Change+$0.09 (+6.21%)
Volume$12.72M
Capitalization122.59M
DNA vs PLX Comparison Chart in %
Loading...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNA vs. PLX commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNA is a Buy and PLX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (DNA: $9.44 vs. PLX: $1.54)
Brand notoriety: DNA and PLX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNA: 605% vs. PLX: 987%
Market capitalization -- DNA: $553.71M vs. PLX: $122.59M
DNA [@Biotechnology] is valued at $553.71M. PLX’s [@Biotechnology] market capitalization is $122.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNA’s FA Score shows that 1 FA rating(s) are green whilePLX’s FA Score has 1 green FA rating(s).

  • DNA’s FA Score: 1 green, 4 red.
  • PLX’s FA Score: 1 green, 4 red.
According to our system of comparison, DNA is a better buy in the long-term than PLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNA’s TA Score shows that 6 TA indicator(s) are bullish while PLX’s TA Score has 6 bullish TA indicator(s).

  • DNA’s TA Score: 6 bullish, 4 bearish.
  • PLX’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, PLX is a better buy in the short-term than DNA.

Price Growth

DNA (@Biotechnology) experienced а +10.15% price change this week, while PLX (@Biotechnology) price change was +10.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

PLX is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNA($554M) has a higher market cap than PLX($123M). DNA YTD gains are higher at: -3.870 vs. PLX (-18.085). PLX has higher annual earnings (EBITDA): 7.16M vs. DNA (-387.59M). DNA has more cash in the bank: 517M vs. PLX (34.7M). PLX has less debt than DNA: PLX (5.24M) vs DNA (435M). DNA has higher revenues than PLX: DNA (237M) vs PLX (59.8M).
DNAPLXDNA / PLX
Capitalization554M123M450%
EBITDA-387.59M7.16M-5,413%
Gain YTD-3.870-18.08521%
P/E RatioN/A30.80-
Revenue237M59.8M396%
Total Cash517M34.7M1,490%
Total Debt435M5.24M8,308%
FUNDAMENTALS RATINGS
PLX: Fundamental Ratings
PLX
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
65
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
10
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNAPLX
RSI
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
87%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 17 days ago
87%
Bearish Trend 13 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
Aroon
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MHVYF25.470.86
+3.49%
Mitsubishi Heavy Industries Ltd.
NCRRP1072.73N/A
N/A
NCR Voyix Corporation
PPRQF10.75-0.03
-0.26%
Choice Properties Real Estate Invt Trust
RZSMF1.15-0.05
-4.17%
Rizzoli Corriere della Sera Mediagroup SPA AZ
GHYLF0.45-0.15
-25.00%
Gold Hydrogen Limited

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with ABCL. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
-1.77%
ABCL - DNA
52%
Loosely correlated
-3.48%
CRSP - DNA
51%
Loosely correlated
N/A
NTLA - DNA
48%
Loosely correlated
-0.52%
RXRX - DNA
48%
Loosely correlated
-6.85%
ABSI - DNA
45%
Loosely correlated
-3.32%
More

PLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PLX has been loosely correlated with IOVA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PLX jumps, then IOVA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PLX
1D Price
Change %
PLX100%
+6.21%
IOVA - PLX
50%
Loosely correlated
-5.06%
SRRK - PLX
32%
Poorly correlated
+0.93%
SNDX - PLX
30%
Poorly correlated
-2.80%
DNA - PLX
29%
Poorly correlated
-1.77%
ZNTL - PLX
29%
Poorly correlated
-6.35%
More